Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2024 | Using MRD to guide treatment decisions in myeloma

Karthik Ramasamy • 28 Apr 2024
BSH 2024
Multiple Myeloma

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the potential for using measurable residual disease (MRD) status to guide treatment decisions in clinical practice. Patients with multiple myeloma (MM) who achieve MRD-negativity may be able to discontinue treatment early and undergo a treatment-free interval. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Karthik Ramasamy

2:13
Frontline treatment of transplant eligible patients with myeloma: current approach & future changes
Karthik Ramasamy • 28 Apr 2024
1:33
Post-hoc analysis of TOURMALINE-MM1 data while adjusting for subsequent therapies
Karthik Ramasamy • 28 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
0:46
The urgency of diagnosing and treating patients with Castleman disease
Karthik Ramasamy • 28 Apr 2024

Related Videos

1:50
The recent expanded approval of cilta-cel into earlier lines of myeloma therapy
Roberto Mina • 23 Apr 2024
2:13
Frontline treatment of transplant eligible patients with myeloma: current approach & future changes
Karthik Ramasamy • 28 Apr 2024
History and upcoming projects of the MMRF
Hearn Jay Cho et al. • 3 May 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals